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Abstract
Introduction: Fibroblast growth factor 21 FGF-21 is a newly discovered adipocytokine which may play a vital role in improvement of
insulin sensitivity and pathogenesis of type 2 diabetes.
The aim of the study was to assess FGF-21 concentrations in the serum of patients with type 2 diabetes, in comparison to a control group,
and evaluate the possible relationships between the studied cytokine and selected clinical and biochemical parameters
Material and methods: The study was conducted in 64 patients with type 2 diabetes, 28 women and 36 men aged 47–70 (median age 61.5),
with a median duration of diabetes of 8.5 years. In fasting serum samples, concentrations of glucose, insulin, lipids profile parameters,
creatinine, C-reactive protein (CRP), fibrinogen, HbA1c, adiponectin, and FGF-21 were determined. The control group comprised 20 heal-
thy persons matched for age to the study group, with no disturbances in carbohydrate metabolism: 14 women and 8 men.
Results: We found significant differences concerning the medians of body mass index (BMI) 32.4 kg/m2 v. 24.1 kg/m2, p < 0.001; waist
circumference 114 cm v. 81 cm, p < 0.001; HDL cholesterol 42.5 mg/dl v. 62.5 mg/dl, p < 0.001; triglyceride (TG) 152 mg/dl v. 99 mg/dl,
p < 0.01 in the studied group, in comparison with the control group, respectively.
In patients with diabetes, median FGF-21 concentration was 239.9 pg/ml and was significantly greater in comparison to the control group:
112.6 pg/ml p < 0.01. Median adiponectin concentration in patients with type 2 diabetes was significantly lower in comparison to the
control group, 7.5 ng/ml v. 9.95 ng/ml, p < 0.05.
Significant correlations between FGF-21 concentrations and adiponectin (r = –0.24, p < 0.05), weight (r = 0.27, p < 0.05), glucose (r = 0.27,
p < 0.05), HDL cholesterol (r = –0.26, p < 0.05), TG (r = 0.27, p < 005), and estimated glomerular filtration rate (eGFR) (r = –0.28, p < 0.05)
were observed. No significant correlations between FGF-21 and parameters of metabolic control, markers of inflammatory status, and
insulin resistance, or the presence of vascular complications of diabetes, were noticed.
Conclusions: On the basis of the conducted studies it can be concluded that the greater FGF-21 concentration observed in the examined
group of patients with type 2 diabetes may result from a compensatory reaction to metabolic disturbances or tissue resistance to this
cytokine. The negative correlation between FGF-21 and eGFR suggests renal elimination of the examined compound.
(Pol J Endocrinol 2010; 61 (1): 50–54)
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Streszczenie
Wstęp: Czynnik wzrostu fibrolastów 21 (FGF-21, fibroblast growth factor 21) jest stosunkowo niedawno odkrytą adipokiną, mogącą odgry-
wać istotną rolę w poprawie insulinowrażliwości i patogenezie cukrzycy tytu 2. Celem pracy była ocena stężenia FGF-21 w surowicy krwi
pacjentów cukrzycą typu 2 w porównaniu z grupą kontrolną, oraz znalezienie zależności pomiędzy tą cytokiną a innymi parametrami
klinicznymi i biochemicznymi.
Materiał i metody: Badania wykonano u 64 pacjentów z cukrzycą typu 2, w tym 28 kobiet i 36 mężczyzn w wieku 47–70 lat (średnia wieku
61,5), z medianą czasu trwania choroby 8,5 roku. W próbkach krwi pobranej na czczo wykonywano oznaczenia stężeń glukozy, insuliny,
białka C-reaktywnego (CRP, C-reactive protein), fibrynogenu, lipidogramu, kreatyniny, HbA1c, adiponektyny i FGF-21. Grupę kontrolną
stanowiło 20 osób (14 kobiet i 8 mężczyzn) z medianą wieku 58 lat, bez zaburzeń gospodarki węglowodanowej.
Wyniki: W grupie badanej stwierdzono, w porównaniu z grupą kontrolną, istotne różnice w zakresie median wskaźnika masy ciała (BMI,
body mass index) 32,4 kg/m2 v. 24,1 kg/m2, p < 0,001; obwodu talii 114 cm v. 81 cm, p < 0,001; cholesterolu frakcji HDL 42,5 mg/dl v. 62,5 mg/dl,
p < 0,001; triglicerydów (TG, triglyceride) 152 mg/dl v. 99 mg/dl, p < 0,01. U pacjentów z cukrzycą mediana stężenia FGF-21 wynosiła
239,8 pg/ml i była istotnie wyższa w porównaniu z grupą kontrolną: 112,6pg/ml, p < 0,001. Mediana stężenia adiponektyny u pacjentów
z cukrzycą była istotnie niższa w porównaniu z grupą kontrolną, 7,5 ng/ml v. 9,95 ng/ml, p < 0,01. Zaobserwowano istotne zależności
pomiędzy stężeniami FGF-21 a adiponektyną (r = –0,24, p < 0,05), masą ciała (r = 0,27, p < 0,05), glukozą (r = 0,27, p < 0,05), cholestero-
lem frakcji HDL (r = –0,26, p < 0,05), TG (r = 0,27, p < 005) oraz wielkością przesączania kłębuszkowego (eGFR, estimated glomerular
filtration rate) (r = –0,28, p < 0,05). Nie znaleziono istotnych zależności pomiędzy stężeniem FGF-21 a parametrami wyrównania metabo-
licznego, wykładnikami stanu zapalnego i insulinooporności, jak również obecnością powikłań naczyniowych choroby.
Wnioski: Na podstawie przeprowadzonych badań można przypuszczać, że obserwowane wyższe stężenia FGF-21 w badanej grupie
pacjentów z cukrzycą typu 2, mogą wynikać z kompensacyjnej reakcji na zaburzenia metaboliczne bądź też są wynikiem tkankowej
oporności na tę cytokinę. Ujemna korelacja stężeń FGF-21 z eGFR sugeruje eliminację drogą nerkową badanego związku.
(Endokrynol Pol 2010; 61 (1): 50–54)
Słowa kluczowe: FGF-21, cukrzyca typu 2, insulinooporność, adipocytokiny
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Introduction
Diabetes, especially type 2 diabetes, which is strongly
connected with visceral obesity and insulin resistance,
has become an increasing global health problem in re-
cent years. The perception of adipose tissue as a rese-
rvoir of fatty acids has been replaced in recent years by
the assumption that adipose tissue plays a vital role in
lipid and glucose metabolism and produces a large num-
ber of hormones and cytokines which generate insulin
resistance [1]. Visceral obesity aggravates insulin resi-
stance and there has been much interest in the possible
role of adipose tissue adipocytokines. It is well known
that adipocytes produce and secrete a variety of biolo-
gically active mediators (adipocytokines), which are
thought to contribute to the development of insulin
resistance, type 2 diabetes, and cardiovascular disease.
Fibroblast growth factors (FGFs) are hormonal fac-
tors with various biological functions. The human FGF
family includes 22 members that are divided into seven
subfamilies based on structure and sequence identity.
While most FGFs act as local regulators of cell growth
and differentiation, recent studies indicated that FGF-
19 subfamily members including FGF-15/19, FGF-21,
and FGF-23, sharing approximately 30% of their amino
acid sequence homology, exert important metabolic ef-
fects in an endocrine fashion [2].
Fibroblast growth factor 21 (FGF-21), a member of
the FGF-19 subfamily, is a newly discovered adipocy-
tokine with potent antidiabetic properties [3]. FGF-21
is believed to be a metabolic regulator, which in animal
models has been shown to improve glucose metabo-
lism and insulin sensitivity.
A full-length FGF-21 molecule consisting of 210
amino acids was cloned in 2000 and mapped to chro-
mosome 19. A mature FGF-21 built of 181 amino acids
has recently emerged as an important metabolic regu-
lator of glucose and lipid metabolism. FGF-21 exerts its
metabolic action via FGFRs with the use of the cofactor
b Klotho [4–6]. Restricted expression of b Klotho limits
FGF-21 action primarily in the liver, pancreas, and adi-
pose tissue [7]. FGF-21 is mainly expressed in hepatocy-
tes and in the pancreas, but also originates from adipose
and muscle tissue, where it is regulated by the peroxiso-
me proliferators-activated receptors, PPARg and PPARa
[8]. FGF-21 stimulates glucose uptake in differentiated
mouse 3T3-L1 cells and human adipocytes [9]. Impor-
tantly, this effect on glucose uptake is insulin indepen-
dent. It has been reported that in isolated pancreatic is-
lets, FGF-21 also suppressed glucose-mediated glucagon
release and stimulated insulin secretion, which may sug-
gest direct protection from the glucolipotoxicity effect on
pancreatic a and b cells [3]. Interestingly, FGF-21 unlike
classical FGFs, has not been reported to induce prolifera-
tion or to be a mitogenic factor.
FGF-21 is believed to be a major metabolic regulator
of glucose and lipid homeostasis and obesity. Kharito-
nenkov et al. demonstrated that in transgenic mice with
overexpression of FGF-21, a lean, insulin-sensitive phe-
notype was observed. FGF-21 transgenic mice have
improved metabolic profiles: reduced glucose, insulin,
cholesterol and triglyceride levels, insulin sensitivity,
and resistance to diet-induced and age-induced weight
gain and fat accumulation [9, 10]. Moreover, contrary
to these observations, the lack of FGF-21 led to incre-
ased body weight, development of fatty liver disease,
impaired glucose tolerance, and increased insulin resi-
stance. Data suggest that FGF-21 is also involved in re-
gulation of ketogenesis, fatty acid oxidation, and ada-
ptive response to starvation [11]. The research of many
others, such as Coskun T et al. and Hu J et al. shows
that when administered to animals, this adipocytokine
promotes improved and sustained glucose and lipid
control, reduced insulin resistance, preservation of
b-cell mass and function, and correction of obesity [12,
13]. Kharitonenkov et al. also evaluated FGF-21 bioacti-
vity in diabetic nonhuman primates [14]. After six we-
ek’s administration of FGF-21 to diabetic rhesus mon-
keys, a significant decrease in fasting plasma glucose,
fructosamine, triglycerides, insulin, and glucagons was
observed. What is important, especially for safety pur-
poses, hypoglycaemia and cell proliferation was not
observed at any point during the study. FGF-21 admi-
nistration also led to significant amelioration of lipopro-
tein profiles, including lowered low-density lipoprote-
in (LDL) cholesterol and raised high-density lipoprote-
in (HDL) cholesterol. On the basis of the results obta-
ined from the studies, it may be supposed that FGF-21
action in animal models is not associated with serious
side-effects of hypoglycaemia, oedema, liver toxicity,
adiposity, mitogenicity, lipodystrophy, or excessive
weight loss, even in suprapharmacologic doses [14, 15].
However, very little is known about changes in serum
FGF-21 levels and its regulation in humans. It seems inte-
resting to elucidate the role of this adipocytokine in
patients with long-lasting type 2 diabetes. The aim of
the conducted study was the assessment of FGF-21 con-
centrations in the serum of patients with type 2 diabe-
tes, and an attempt to evaluate the possible relation-
ship between the studied adipocytokine and selected
clinical and biochemical parameters.
Material and methods
The study included 64 randomly chosen patients with
type 2 diabetes mellitus hospitalized in the Department
of Endocrinology of the Medical University of Lublin.
The examined group consisted of 28 women and 36 men
aged from 47 to 70 (with median age 61.5). The median
duration of the disease was 8.5 years. The study pro-
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tocol was approved by the local Ethics Committee
(KE-0254/135/2009). Written informed consent was ob-
tained from every patient qualified to enter the study.
All patients underwent clinical examination. The pre-
valence and the degree of severity of chronic vascular
complications of the disease were evaluated clinically.
In fasting serum samples, with the use of routine
laboratory methods we determined concentrations of
glucose, insulin, CRP, fibrinogen, creatinine, triglyceri-
des, total cholesterol, and HDL cholesterol (LDL-cho-
lesterol was calculated according to the Friedewald for-
mula) at the time of admission to the Department of
Endocrinology. FGF-21 and adiponectin concentrations
were also measured at this time using a solid phase en-
zyme-linked immunosorbent assay, based on the prin-
ciple of competitive binding (Human FGF-21 ELISA Kit,
Human Adiponectin ELISA Kit; BioVendor, Modrice,
Czech Republic) according to the manufacturer’s in-
structions. Homeostasis model assessment of insulin
resistance (HOMA-IR) was calculated as follows: as the
product of the fasting insulin expressed as mU/ml and
fasting values of glucose expressed as mg/dl divided by
the constant 405 (FI*FG/405). Estimated glomerular
filtration rate (eGFR) was calculated using the Modifi-
cation of Diet in Renal Disease (MDRD) formula, such
as eGFR = 186 × Serum Creatinine –1,154 × Age–0,203 ×
× [0.742, if Female].
The control group comprised 20 healthy persons
matched for age to the study group, with no disturban-
ces in carbohydrate metabolism, 14 women and 8 men,
undergoing prophylactic examination in the Depart-
ment of Laboratory Diagnostics of the Medical Univer-
sity of Lublin.
The results of the conducted studies were statisti-
cally analysed using basic parameters of descriptive sta-
tistics (median ± interquartile range). Partial Spearman
correlation coefficients between FGF-21 serum concen-
trations and other laboratory parameters were calcula-
ted. Statistical analyses were conducted using the Stati-
stica version 8.0 programme. P < 0.05 was considered
significant.
Results
Baseline characteristics of the study population are pre-
sented in Table I. In the examined group of patients
with type 2 diabetes, significant differences concerning
weight, BMI, waist circumference, and parameters of
blood pressure in comparison to the control group were
observed. The biochemical characteristics of the study
population are shown in Table II. As a result of the con-
ducted studies it was found that FGF-21 concentration
in patients with type 2 diabetes was significantly eleva-
ted in comparison with the control group. Adiponectin
concentrations were significantly lower than those ob-
served in the control group were. Glucose, HbA1c, CRP,
fibrinogen, TG, and creatinine levels were significantly
increased in the study group compared to the control
group, whereas HDL cholesterol plasma concentration
and eGFR values were significantly decreased. Univa-
riate correlations of circulating FGF-21 concentrations
are presented in Table III. Serum FGF-21 concentrations
were directly proportional to weight and waist circum-
ference, fasting glucose, and triglycerides. We demon-
strated a significant negative correlation existing betwe-
Table II. Biochemical characteristics of the study population
Tabela II. Charakterystyka biochemiczna badanej populacji
Control DM p
Number of cases 20 64 –
FGF-21 [pg/ml] 112.6±125.1 239.8±243.6  < 0.001
Adiponectin [ng/ml] 9.95±3.65 7.50±4.71  < 0.01
Glucose [mg/dl] 88.0±10.0 150.5±42.0  < 0.001
HbA1c (%) 5.5±0.5 8.6±2.8  < 0.001
CRP [mg/L] 0.91±1.2 3.51±4.17  < 0.05
Fibrinogen [g/L] 2.65±0.37 4.50±1.28  < 0.01
Total cholesterol 214±81 196±59 NS
[mg/dl]
HDL cholesterol 62.5±10.2 42.5±17.1  < 0.001
[mg/dl]
LDL cholesterol 131.2±61.8 114.4±41.0 NS
[mg/dl]
Triglycerides [mg/dl] 99±50 152±119  < 0.01
eGFR (MDRD) 110.1±19.2 71.7±24.3  < 0.001
[ml/min/1.73 m2]
Creatinine [mg/dl] 0.71±0.11 1.00±0.35  < 0.05
Values are shown as median ± interquartile range
Table I. Baseline characteristics of the study population
Tabela I. Charakterystyka badanej populacji
Control DM p
Number of cases 20 64 –
Duration of diabetes – 8.5±11.5 –
(years)
Age (years) 58.0±13.0 61.5±9.5 NS
Weight [kg] 64.0±21.0 85.5±15.0  < 0.001
BMI [kg/m2] 24.1±4.0 32.4±6.6  < 0.001
Waist 81±22 114±14  < 0.001
circumference [cm]
Systolic blood 130±20 140±20  < 0.001
pressure [mm Hg]
Diastolic blood 70±10 85±10  < 0.001
pressure [mm Hg]
Pulse pressure [mm Hg] 50±10 60±10  < 0.01
Values are shown as median ± interquartile range
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en FGF-21 and adiponectin, HDL cholesterol, and eGFR
values. Circulating FGF-21 levels were not correlated
with age, sex, BMI, blood pressure, HbA1c, CRP and fi-
brinogen. We did not observe any significant correla-
tions between FGF-21 and insulin concentrations, and
HOMA-IR and the number and type of vascular diabe-
tic complications.
Discussion
FGF-21 has recently been introduced as a novel adipo-
kine improving tissue sensitivity to insulin and exer-
ting beneficial effects on glucose and lipid metabolism
in animal models. [9]. In the current study, FGF-21 pla-
sma concentrations were determined for the first time
in patients with long-lasting type 2 diabetes mellitus
with micro- and macrovascular complications and me-
dian disease duration of more than eight years. We de-
monstrated that FGF-21 plasma levels are significantly
elevated in patients with type 2 diabetes compared to
the control group. As mentioned previously, numero-
us animal studies suggest that FGF-21 is a potent meta-
bolic regulator with multiple beneficial effects on insu-
lin resistance state, so our results in patients with type 2
diabetes seem to be controversial. However, our data
are consistent with a recent study by Zhang and co-
workers, in which serum FGF-21 concentrations were
determined in 232 subjects from the community-based
Hong Kong Cardiovascular Risk Factor Prevalence Stu-
dy [16]. The results of the current studies conducted in
humans revealed that FGF-21 is increased in subjects
with diabetes, obesity, and lipid disorders [16, 17]. The
results of the first studies conducted on people were
very surprising, since blood serum FGF-21 concentra-
tions in obese people, especially those with central obe-
sity in the course of the metabolic syndrome, were fo-
und to be significantly increased. What is interesting, it
could be observed that along with an increase in struc-
tural components of the metabolic syndrome, FGF-21
concentration increased progressively [16]. It was even
suggested that FGF-21 could be a potential biomarker
of increased risk of the metabolic syndrome.
In our study we confirmed that circulating FGF-21
is significantly and positively associated with weight
and waist circumference, fasting glucose, and TG, whe-
reas a negative correlation exists with HDL cholesterol.
We failed to observe significant associations between
markers of insulin resistance such as fasting insulin and
HOMA-IR, which has been proven in research by others
authors [16, 17]. These studies support the notion that
FGF-21 might be part of a physiological feedback me-
chanism improving insulin signalling in insulin resistan-
ce-associated conditions including visceral obesity, type
2 diabetes mellitus, and other cardiovascular diseases.
What is interesting to note, in Kharitonenkov’s research,
the metabolic parameters were significantly influenced
in diabetic rhesus monkeys by FGF-21 treatment [14].
Thus, FGF-21 induced a significant decrease in fasting
insulin and TG, whereas HDL cholesterol and adipo-
nectin were increased. On the other hand, the insulin
resistance and/or dyslipidaemia might cause resistance
to FGF-21, leading to compensatory up-regulation of
this antidiabetic adipocytokine.
The physiological relevance of increased FGF-21 le-
vels in patients with type 2 diabetes remains to be de-
termined. On the basis of the results obtained, this may
suggest a compensatory mechanism of the observed
changes or tissue resistance to FGF-21. The mechani-
sms leading to increased levels of FGF-21 in patients
with type 2 diabetes and insulin resistance are still unc-
lear. It should be noted that FGF-21 is produced mostly
in the liver, but also in a wide range of other tissues,
such as adipose and muscle tissue, and modulation of
FGF-21 concentration might be tissue specific. Further
research concerning assessment of FGF-21 receptors in
peripheral tissue is needed to elucidate the role and re-
gulation of this novel adipocytokine in type 2 diabetes.
In the current study no correlation with FGF-21 con-
centration was observed in the studied group of patients
with diabetes complicated with micro- and macroan-
giopathy, regardless of the severity or number of com-
Table III. Univariate correlations of serum FGF-21
concentrations
Tabela III. Korelacje osoczowego stężenia FGF-21 w analizach
jednoczynnikowych
r p
Duration of diabetes (years) 0.19 0.09
Adiponectin [ng/ml] –0.24  < 0.05*
Age (years) 0.2 0.09
Weight [kg] 0.27  < 0.05*
BMI [kg/m2] 0.22 0.06
Waist circumference [cm] 0.3  < 0.01*
Systolic blood pressure [mm Hg] 0.12 0.31
Diastolic blood pressure [mm Hg] 0.07 0.55
Pulse pressure [mm Hg] 0.12 0.28
Glucose [mg/dl] 0.27  < 0.05*
HbA1c (%) 0.02 0.845
CRP [mg/L] 0.16 0.185
Fibrinogen [g/L] 0.04 0.742
Total cholesterol [mg/dl] –0.03 0.793
HDL cholesterol [mg/dl] –0.26  < 0.05*
LDL cholesterol [mg/dl] 0.002 0.983
Triglycerides [mg/dl] 0.27  < 0.05*
eGFR (MDRD) [ml/min/1.73 m2] –0.27  < 0.05*
Creatinine [mg/dl] 0.22 0.08
*Significant correlations as assessed by Spearman correlation method
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plications. In our project we noticed a significant nega-
tive relationship between FGF-21 and renal function
expressed as eGFR calculated with the use of the MDRD
formula. Our findings are in close accordance with Ste-
in’s data [18]. Stein et al. demonstrated a statistically
significant relation of this adipocytokine to renal func-
tion. They found that circulating levels of FGF-21 were
more than 15-fold higher in patients with chronic kid-
ney disease maintained on haemodialysis in compari-
son to the control group. On the basis of the results
obtained from the studies, we can suppose that this
adipocytokine is eliminated via the renal route. A nega-
tive correlation of FGF-21 concentrations with eGFR va-
lues may also indicate accumulation of the examined
compound in the body as an effect of progressing renal
insufficiency. It can also be concluded that serum creati-
nine or other markers of renal function should always
be included in studies concerning FGF-21 physiology.
The physiological significance of increased FGF-21 con-
centrations in renal failure requires further investigation.
What is interesting, similarly to our data, a negative
association between FGF-21 and circulating serum adi-
ponectin has also been found in subjects with the me-
tabolic syndrome and patients with anorexia nervo-
sa [16, 20]. The role of adiponectin as an independent
metabolic marker of increased cardiovascular risk was
previously well established. [21–23]. In Dostalova’s stu-
dy, adiponectin remains an independent predictor of
circulating FGF-21 [24].
Considering these observations together, FGF-21
serum concentrations showed a significant association
with metabolic and vascular risk factors, including de-
creased adiponectin and atherogenic lipid profile (in-
creased TG, decreased HDL cholesterol) in univariate
analysis. These results suggest that FGF-21 might be
a novel marker up-regulated in type 2 diabetic patients.
This paradoxical up-regulation of FGF-21 might be
a compensatory mechanism to improve glucose meta-
bolism when insulin resistance and an atherogenic li-
pid profile are present. Prospective studies are needed
to better elucidate the role of FGF-21 in metabolic and
cardiovascular disease.
Conclusions
1. On the basis of the conducted research, it can be sup-
posed that the higher FGF-21 concentrations obse-
rved in the study group of patients with type 2 dia-
betes may result from a compensatory reaction to
metabolic disturbances or tissue resistance to this
adipocytokine .
2. A negative correlation of FGF-21 concentrations with
eGFR values may suggest renal elimination of the
studied compound and indicate its accumulation in
the body as an effect of progressing renal insuffi-
ciency.
3. Further investigations are required to determine the
clinical consequences of the observed changes and
answer the question whether FGF-21 might be
a novel marker up-regulated in type 2 diabetic
patients.
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